Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Dermatologic 1

Conditions

Melanoma 9Neoplasm Metastasis 3Urinary Bladder Neoplasms 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 58Nivolumab 37aldesleukin 16Cyclophosphamide 15atezolizumab 12Specimen Handling 11Radiosurgery 10Paclitaxel 10Magnetic Resonance Spectroscopy 10Ipilimumab 9Interleukin-2 9fludarabine 8fludarabine phosphate 7Docetaxel 7Carboplatin 7avelumab 6Radiotherapy 6durvalumab 5Peripheral Blood Stem Cell Transplantation 5Immune Checkpoint Inhibitors 5Cisplatin 5Bevacizumab 5tislelizumab 4temsirolimus 4spartalizumab 4Sirolimus 4Pemetrexed 4Oxaliplatin 4Leucovorin 4Cryosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Decitabine × Dermatologic × Clear all
NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Terminated
252 enrolled 67 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡